Major differences in COVID patient care caused by insufficient data, misleading advice
Government should commit to making GP premises carbon neutral by 2030, say leaders
12 May 2021Slovakia plans to keeping using AstraZeneca despite pause
12 May 2021Major differences in COVID patient care caused by insufficient data, misleading advice
While there was extensive use of drug repurposing throughout the first 10 months of the COVID-19 pandemic, there was substantial heterogeneity over the types of drugs used for treatment purposes globally. Some drugs, including hydroxychloroquine, saw sharp declines in use, while adjunctive therapies grew into a more relied upon method for patient management.
